Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract

This study has suspended participant recruitment.
(Lack of recruitment)
Information provided by (Responsible Party):
Laboratorios Leti, S.L. Identifier:
First received: January 10, 2008
Last updated: July 14, 2015
Last verified: January 2009
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract Dermatophagoides pteronyssinus in children with allergic asthma due to this mite

Condition Intervention Phase
Allergic Asthma
Biological: DEPIGOID Dermatophagoides pteronyssinus
Biological: Polymerized TOL of Dermatophagoides pteronyssinus
Biological: Placebo Comparator
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Depigmented and Polymerised Allergenic Extract of Dermatophagoides Pteronyssinus as Antiasthmatic Treatment for Children With Slight Allergic Asthma to Mites

Resource links provided by NLM:

Further study details as provided by Laboratorios Leti, S.L.:

Primary Outcome Measures:
  • Symptom and medication scores [ Time Frame: 1 year per patient ]

Secondary Outcome Measures:
  • Comparison between sublingual and subcutaneous administration route, quality of life, cost-effectiveness, dose response prick-test, inflammatory markers, exhaled nitric oxide, inflammatory markers in exhalate bronchial condensate, use of health resources [ Time Frame: 1 year per patient ]
  • Quality of life [ Time Frame: 1 year ]
  • Cost-effectiveness [ Time Frame: 1 year ]
  • Dose response prick-test [ Time Frame: 1 year ]
  • Inflammatory markers [ Time Frame: 1 year ]
  • Use of health resources [ Time Frame: 1 year ]

Estimated Enrollment: 90
Study Start Date: January 2008
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Subcutaneous administration
Biological: DEPIGOID Dermatophagoides pteronyssinus
Subcutaneous administration:0.5 ml/month during 1 year
Experimental: B
Sublingual administration
Biological: Polymerized TOL of Dermatophagoides pteronyssinus
Sublingual immunotherapy. Two drops daily during 1 year
Placebo Comparator: C
Sublingual administration
Biological: Placebo Comparator
Sublingual immunotherapy. Two drops daily during 1 year

Detailed Description:
Immunotherapy is a specific treatment for allergic diseases. Unlike conventional pharmacological treatment, immunotherapy is the only treatment that could modify the natural course of allergic disease. This is a prospective double-blind placebo controlled study with three arms of treatment: placebo and two active (one of the active arms will receive subcutaneous immunotherapy and the other one will receive sublingual immunotherapy).

Ages Eligible for Study:   5 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent signed by the patient and guardian.
  • Positive clinical history of allergy to dust mites.
  • FEV1 greater than or equal to 80% of the expected value and improvement in FEV1 greater than 12% after bronchodilation.
  • Age-between 5 and 14 years.
  • Sensitization to dust mites, diagnosed by positive skin tests to Dermatophagoides pteronyssinus: wheal size > 3 mm diameter and / or RAST (> 0.7 kU / L).

Exclusion Criteria:

  • Patients out of the age range.
  • Use of immunotherapy during the last four years.
  • Any contraindication for the use of immunotherapy in accordance with European Allergy and Clinical Immunology Immunotherapy Subcommittee criteria:

    • Treatment with ß-blockers
    • Patients who have a condition in which adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc..).
    • Coexistence of immunopathological diseases (e.g. of the liver, kidney, the nervous system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role
    • Patients suffering from immune deficiencies
    • Patients with serious psychiatric / psychological disturbances
  • Patients aspirin intolerance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00622362

Hospital Universitario La Fé
Valencia, Spain, 46009
Sponsors and Collaborators
Laboratorios Leti, S.L.
Principal Investigator: Antonio Nieto, MD PhD
  More Information

Responsible Party: Laboratorios Leti, S.L. Identifier: NCT00622362     History of Changes
Other Study ID Numbers: 2006-000571-15
Study First Received: January 10, 2008
Last Updated: July 14, 2015

Keywords provided by Laboratorios Leti, S.L.:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on April 28, 2017